Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer

Berry, Donald A.; Cronin, Kathleen A.; Plevritis, Sylvia K.; Fryback, Dennis G.; Clarke, Lauren; Zelen, Marvin; Mandelblatt, Jeanne S.; Yakovlev, Andrei; Habbema, J. Dik F.; Feuer, Eric J.

doi:10.1056/nejmoa050518

Cited by 2,137 publications

(1,151 citation statements)

References 20 publications

Supporting

Mentioning

1,083

Contrasting

Unclassified

Order By: Relevance

“…Breast cancer patients overexpressed with HER2 are associated with poor prognosis 22. HER2‐targeted therapy for HER2‐positive breast cancer patients has dramatically improved the survival rate and reduced mortality in recent history 23. HER2 gene amplification was first associated with worse clinical outcomes in the late 1980s by Slamon et al, and the following serious of studies revealed that residents at Asian‐Pacific areas were with high occurrence rate to be diagnosed with HER2‐positive status with a poorer diagnosis in comparison with other regions 24, 25, 26.…”

Section: Discussionmentioning

confidence: 99%

Long non‐coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation

Huang

Wang

et al. 2018

J Cellular Molecular Medi

100

View full text Add to dashboard Cite

Currently, resistance to trastuzumab, a human epidermal growth factor receptor 2 (HER2) inhibitor, has become one major obstacle for improving the clinical outcome of patients with advanced HER2+ breast cancer. While cell behaviour can be modulated by long non‐coding RNAs (lncRNAs), the contributions of lncRNAs in progression and trastuzumab resistance of breast cancer are largely unknown. To this end, the involvement and regulatory functions of lncRNA SNHG14 in human breast cancer were investigated. RT‐qPCR assay showed that SNHG14 was up‐regulated in breast cancer tissues and associated with trastuzumab response. Gain‐ and loss‐of‐function experiments revealed that overexpression of SNHG14 promotes cell proliferation, invasion and trastuzumab resistance, whereas knockdown of SNHG14 showed an opposite effect. PABPC1 gene was identified as a downstream target of SNHG14, and PABPC1 mediates the SNHG14‐induced oncogenic effects. More importantly, ChIP assays demonstrated that lncRNA SNHG14 may induce PABPC1 expression through modulating H3K27 acetylation in the promoter of PABPC1 gene, thus resulting in the activation of Nrf2 signalling pathway. These data suggest that lncRNA SNHG14 promotes breast cancer tumorigenesis and trastuzumab resistance through regulating PABPC1 expression through H3K27 acetylation. Therefore, SNHG14 may serve as a novel diagnostic and therapeutic target for breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Long non‐coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation

Huang

Wang

et al. 2018

J Cellular Molecular Medi

100

View full text Add to dashboard Cite

show abstract

“…Screening mammography is currently the most effective way to detect breast abnormalities and has led to an estimated 10-25 % mortality reduction from breast cancer [1,2]. Even as mammography use has reached a plateau in recent years [3], mammography usage varies by state [4] and a significant proportion of women are not up-to-date with screening, especially low-income women, those who are uninsured [5,6] and those without usual source of care [7].…”

Section: Introductionmentioning

confidence: 99%

Characteristics of US Counties with No Mammography Capacity

et al. 2012

View full text Add to dashboard Cite

Access to screening mammography may be limited by the availability of facilities and machines, and nationwide mammography capacity has been declining. We assessed nationwide capacity at state and county levels from 2003 to 2009, the most recent year for which complete data were available. Using mammography facility certification and inspection data from the Food and Drug Administration, we geocoded all mammography facilities in the United States and determined the total number of fully accredited mammography machines in each US County. We categorized mammography capacity as counties with zero capacity (i.e., 0 machines) or counties with capacity (i.e.,≥1 machines), and then compared those two categories by sociodemographic, health care, and geographic characteristics. We found that mammography capacity was not distributed equally HHS Public Access Author Manuscript Author ManuscriptAuthor ManuscriptAuthor Manuscript across counties within states and that more than 27 % of counties had zero capacity. Although the number of mammography facilities and machines decreased slightly from 2003 to 2009, the percentage of counties with zero capacity changed little. In adjusted analyses, having zero mammography capacity was most strongly associated with low population density (OR = 11.0; 95 % CI 7.7-15.9), low primary care physician density (OR = 8.9; 95 % CI 6.8-11.7), and a low percentage of insured residents (OR = 3.3; 95 % CI 2.5-4.3) when compared with counties having at least one mammography machine. Mammography capacity has been and remains a concern for a portion of the US population-a population that is mostly but not entirely rural.

show abstract

“…Breast cancer mortality decreased in the US in 2000 for the first time [174], which is partly attributable to improvements in systemic therapy [175]. The progress has been incremental, with each new therapeutic intervention applied to the entire population, including individuals who may have been adequately treated with minimal or no systemic adjuvant therapy.…”

Section: Resultsmentioning

confidence: 99%

Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization

Sparano

Hortobágyi

Gralow

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

Over 9,000 women with breast cancer are enrolled annually on clinical trials sponsored by the National Cancer Institute (NCI), accounting for about one-third of all patients enrolled on NCI-sponsored trials. Thousands are also enrolled on pharmaceutical-sponsored studies. Although breast cancer mortality rates have recently declined for the first time in part due to systemic therapeutic advances, coordinated efforts will be necessary to maintain this trend. The Coalition of Cancer Cooperative Groups convened the Scientific Leadership Council in breast cancer (BC), an expert panel, to identify priorities for future research and current trials with greatest practice-changing potential. Panelists formed a consensus on research priorities for chemoprevention, development and application of molecular markers for predicting therapeutic benefit and toxicity, intermediate markers predictive of therapeutic effect, pathogenesisbased therapeutic approaches, utilization of adaptive designs requiring fewer patients to achieve objectives, special and minority populations, and effects of BC and treatment on patients and families. Panelists identified 13 ongoing studies as High Priority and identified gaps in the current trial portfolio. We propose priorities for current and future clinical breast cancer research evaluating systemic therapies that may serve to improve the efficiency of clinical trials, identify individuals most likely to derive therapeutic benefit, and prioritize therapeutic strategies.

show abstract

Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer

Abstract: Seven statistical models showed that both screening mammography and treatment have helped reduce the rate of death from breast cancer in the United States.

Cited by 2,137 publications

References 20 publications

Long non‐coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation

Long non‐coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation

Characteristics of US Counties with No Mammography Capacity

Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization

Contact Info

Product

Resources

About